Breaking New Ground: Targeting Neutrophil Extracellular Traps (NETs) for Autoimmune Disease Treatment

Introduction

Autoimmune diseases, where the body's immune system mistakenly attacks its own tissues, affect millions worldwide, leading to chronic inflammation, organ damage, and significant morbidity. Conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and vasculitis represent a major healthcare challenge, with current treatments often relying on broad immunosuppressants that come with severe side effects like increased infection risk. Recent advancements, however, point to a promising new target: Neutrophil Extracellular Traps (NETs). These intricate "webs" of DNA and proteins, originally designed to combat infections, can exacerbate autoimmune pathology when dysregulated. Early data from biotech company Neutrolis suggest that breaking down these NETs with a novel enzyme-based therapy could revolutionize treatment, offering rapid, targeted relief without compromising overall immunity.

Understanding Neutrophil Extracellular Traps (NETs)

Neutrophils, the most abundant white blood cells in the human body, serve as the first line of defense against pathogens. In 2004, researchers discovered that activated neutrophils can undergo a process called NETosis, expelling chromatin—strands of DNA laced with antimicrobial proteins like histones, myeloperoxidase (MPO), and neutrophil elastase (NE)—to form extracellular traps. These NETs ensnare and kill bacteria, fungi, and viruses, preventing their spread.

However, NETs are a double-edged sword. In healthy individuals, they are efficiently cleared by natural enzymes like DNase1 and DNase1L3. But in autoimmune diseases, excessive NET formation or impaired clearance leads to their accumulation. This triggers a cascade of harmful effects: exposed DNA and proteins act as autoantigens, stimulating autoantibody production; they promote inflammation by activating other immune cells; and they damage tissues, including blood vessels and organs like the kidneys in lupus.

The Role of NETs in Autoimmune Diseases

Emerging research underscores NETs' pivotal role in various autoimmune and inflammatory conditions. In SLE, for instance, low-density granulocytes produce excessive NETs that resist degradation, leading to lupus flares characterized by skin rashes, joint pain, and kidney damage. Similarly, in RA, NETs contribute to joint inflammation and bone erosion by activating synovial fibroblasts and promoting cytokine release. In vasculitis, NETs damage endothelial cells, causing vessel inflammation and thrombosis.

Recent 2025 studies highlight NETs' involvement in neuropsychiatric lupus, where they disrupt the blood-brain barrier and exacerbate cognitive symptoms. NETs also potentiate effector T cells in autoimmune settings, amplifying adaptive immune responses. Moreover, they drive B-cell activation and autoantibody production, perpetuating the autoimmune cycle. In osteoarticular diseases like ankylosing spondylitis and gout, NETs accelerate disease progression through localized inflammation.

Limitations of Current Autoimmune Treatments

Traditional therapies for autoimmune diseases include corticosteroids, antimalarials like hydroxychloroquine, and biologics targeting specific cytokines (e.g., TNF inhibitors). These can manage symptoms but often fail to address root causes, leading to incomplete remission and side effects such as osteoporosis or immunosuppression. In severe cases, patients face organ failure or require lifelong therapy. The need for precision medicine that targets specific pathological mechanisms without broad immune suppression is evident.

Neutrolis and the Promise of NTR441

Enter Neutrolis, a Boston-based biotech founded in 2020, specializing in therapies that neutralize NETs using its proprietary Chromatinase™ platform. Their lead candidate, NTR441, is an engineered fusion protein combining DNase1L3—an enzyme that naturally cleaves extracellular DNA—with albumin to extend its half-life in the bloodstream.

Originally developed for severe COVID-19, where NETs contribute to lung damage and clotting, NTR441 has pivoted to autoimmune indications. The drug works by "chopping" the DNA backbone of NETs, disintegrating the traps and preventing their inflammatory effects. Unlike upstream inhibitors that block NET formation (potentially weakening infection defenses), NTR441 clears existing NETs downstream, preserving neutrophil function.

In October 2025, Neutrolis secured $50 million in Series A funding from Morningside Ventures to advance NTR441 into clinical trials.

Clinical Data and Proof-of-Concept

Early human data presented at the American College of Rheumatology (ACR) Convergence 2025 provide compelling evidence. In a compassionate use case, a 17-year-old patient with homozygous DNase1L3 deficiency—a rare genetic condition causing unchecked NET accumulation and severe autoimmune symptoms like glomerulonephritis and vasculitis—received a single intravenous dose of NTR441. Remarkably, symptoms resolved within hours: proteinuria dropped dramatically, complement levels normalized, and anti-dsDNA antibodies decreased. The effects persisted for months without recurrence, marking the first clinical validation of direct NET clearance in autoimmunity.

"This is a paradigm shift—directly addressing the NET pathology that's central to these diseases."
— H. Michael Shepard, CEO, Neutrolis

Phase 1 trials confirmed NTR441's safety and tolerability, with no serious adverse events. Ongoing Phase 1/2 studies target moderate-to-severe SLE, with plans for expansion to dry eye disease and other NET-driven conditions.

Comparisons and Competitive Landscape

Neutrolis isn't alone in targeting NETs. InflaRx's vilobelimab inhibits C5a to prevent NET formation, showing promise in vasculitis. Xenikos' T-Guard, for graft-versus-host disease, indirectly modulates NETs. However, NTR441's direct degradation approach may offer faster, more specific action. Challenges remain, including optimizing dosing and ensuring long-term safety, but the field is advancing rapidly.

Future Prospects and Implications

With NETs implicated in over 50 diseases, including cancer (where they promote metastasis), the potential extends beyond autoimmunity. Neutrolis' pipeline includes additional Chromatinase™ molecules for broader applications. If Phase 2 trials succeed, NTR441 could reach patients by the late 2020s, offering hope for those with refractory autoimmune conditions.

Conclusion

The discovery of NETs as a therapeutic target marks a new era in autoimmune disease management. Neutrolis' NTR441 exemplifies precision medicine, potentially transforming lives by dismantling the very "webs" that fuel pathology. As research progresses, this approach could pave the way for safer, more effective treatments, bringing relief to millions suffering from these debilitating disorders. Stay tuned for updates as clinical data unfolds.